Federal Register / Vol. 80, No. 21 / Monday, February 2, 2015 / Notices 5565 

such payments before funding is offered 

to the LRP participant. 

Should an IHS Area Office contribute 

to the LRP, those funds will be used for 

only those sites located in that Area. 

Those sites will retain their relative 

ranking from the national site-ranking 

list. For example, the Albuquerque Area 

Office identifies supplemental monies 

for dentists. Only the dental positions 

within the Albuquerque Area will be 

funded with the supplemental monies 

consistent with the national ranking and 

site index within that Area. 

Should an IHS Service Unit 

contribute to the LRP, those funds will 

be used for only those sites located in 

that Service Unit. Those sites will retain 

their relative ranking from the national 

site-ranking list. For example, 

Whiteriver Service Unit identifies 

supplemental monies for nurses. The 

Whiteriver Service Unit consists of two 

facilities, namely the Whiteriver PHS 

Indian Hospital and the Cibecue Indian 

Health Center. The national ranking will 

be used for the Whiteriver PHS Indian 

Hospital (Score = 79) and the Cibecue 

Indian Health Center (Score = 95). With 

a score of 95, the Cibecue Indian Health 

Center would receive priority over the 

Whiteriver PHS Indian Hospital. 

Dated: January 20, 2015. 

Yvette Roubideaux, 

Acting Director, Indian Health Service. 

[FR Doc. 2015–01958 Filed 1–30–15; 8:45 am] 

BILLING CODE 4165–16–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of Technology Transfer; Notice 

of meetings 

ACTION: Notice of meetings. 

SUMMARY: Notice is hereby given that 

the Office of Intramural Research (OIR), 

National Institutes of Health (NIH), will 

host two webinars to enable public 

discussion of its proposal to reorganize 

the OIR Office of Technology Transfer 

(OTT). The proposal seeks to align 

authority and responsibility for the 

implementation and execution of 

patenting and licensing (P&L) functions 

within the NIH Institutes and Centers. 

DATES: The first webinar will be held on 

February 13th from 9:30 to 10:00 a.m. 

The second webinar will be held on 

February 13th from 10:00 to 10:30 a.m. 

Members of the public wishing to join 

a webinar must register via the webinar 

link provided. Any interested person 

may also file written comments by 

sending an email to Deborah Kassilke, 

kassilked@mail.nih.gov by Tuesday, 

February 17th, 2015. The written 

comment should include the 

commenter’s name and, when 

applicable, professional affiliation. 

ADDRESSES: Session 1: February 13, 

2015 from 9:30 to 10:00 a.m. https://nih.

webex.com/nih/j.php?MTID=m2a6eb

40ebe096afad861f0b5e941f9bc. 

Session 2: February 13, 2015 from 

10:00 to 10:30 a.m. https://nih.webex.

com/nih/j.php?MTID=m8c50a

9e8b5454a39b4fa24d9df412fab. 

FOR FURTHER INFORMATION CONTACT: 

Deborah Kassilke, kassilked@

mail.nih.gov, 301–435–2950. 

SUPPLEMENTARY INFORMATION: The 

background of the proposed OTT 

reorganization is as follows. 

The Advisory Committee to the NIH 

Deputy Director for Intramural 

Research, and the Technology Transfer 

Steering Committee (TTSC) recently 

assessed OTT to determine how it 

services the overall technology transfer 

needs of the NIH. The committees 

recommended that the authority and 

responsibility for the implementation 

and execution of patenting and 

licensing should be decentralized from 

OTT and distributed throughout the 

NIH Institutes and Centers (ICs). In 

September 2014, the NIH Steering 

Committee accepted this 

recommendation. 

Dated: January 27, 2015. 

Lawrence Tabak, 

Principal Deputy Director, National Institutes 

of Health. 

[FR Doc. 2015–01964 Filed 1–30–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke, Muscular 

Dystrophy Coordinating Committee 

Call for Committee Membership 

Nominations 

SUMMARY: The Office of the Secretary of 

the Department of Health and Human 

Services (HHS) is seeking nominations 

of individuals to serve as non-federal 

public members on the Muscular 

Dystrophy Coordinating Committee. 

DATES: Nominations are due by close of 

business, February 27, 2015. 

ADDRESSES: Nominations must be sent 

to Glen Nuckolls, Ph.D., by email to 

nuckollg@ninds.nih.gov. 

FOR FURTHER INFORMATION CONTACT: Glen 

Nuckolls, Ph.D., by email to nuckollg@

ninds.nih.gov. 

SUPPLEMENTARY INFORMATION: The 

Muscular Dystrophy Coordinating 

Committee (MDCC) is a federal advisory 

committee established in accordance 

with the Muscular Dystrophy 

Community Assistance, Research, and 

Education Amendments of 2001 (MD– 

CARE Act; Public Law 107–84. The 

MD–CARE Act was reauthorized in 

2008 by Public Law 110–361, and again 

in 2014 by Public Law 113–166. The 

2014 reauthorization mandated changes 

to the membership of the MDCC, 

resulting in the addition of one public 

member. Nominations of non-federal 

public members will be accepted 

between January 30, 2015 and February 

27, 2015. 

Who is Eligible: Nominations of new 

non-federal public members interested 

in advancing muscular dystrophy 

research and reducing the burden of 

disease are encouraged. Selfnominations and nominations of other 

individuals are both permitted. Only 

one nomination per individual is 

required. Multiple nominations for the 

same individual will not increase 

likelihood of selection. Non-federal 

public members may be selected from 

the pool of submitted nominations and 

other sources as needed to meet 

statutory requirements and to form a 

balanced committee that represents the 

diversity within the muscular dystrophy 

community. Those eligible for 

nomination include leaders or 

representatives of major muscular 

dystrophy research, advocacy, and 

service organizations, parents or 

guardians of individuals with muscular 

dystrophy, individuals with muscular 

dystrophy and service providers, 

educators, researchers, and other 

individuals with professional or 

personal experience with muscular 

dystrophy. In accordance with White 

House Office of Management and 

Budget guidelines (FR Doc. 2014– 

19140), federally-registered lobbyists are 

not eligible. 

Committee Composition: In 

accordance with the Committee’s 

authorizing statute, 2⁄3 of members of the 

Coordinating Committee shall represent 

government agencies and 1⁄3 of members 

shall be public members ‘‘including a 

broad cross section of persons affected 

with muscular dystrophies including 

parents or legal guardians, affected 

individuals, researchers, and 

clinicians.’’ 

The Department strives to ensure that 

the membership of HHS Federal 

advisory committees is fairly balanced 

in terms of points of view represented 

and the committee’s function. Every 

effort is made to ensure that the views 

of women, all ethnic and racial groups, 

mstockstill on DSK4VPTVN1PROD with NOTICES

5566 Federal Register / Vol. 80, No. 21 / Monday, February 2, 2015 / Notices 

and people with disabilities are 

represented on HHS Federal advisory 

committees and, therefore, the 

Department encourages nominations of 

qualified candidates from these groups. 

The Department also encourages 

geographic diversity in the composition 

of the Committee. Appointment to this 

Committee shall be made without 

discrimination on the basis of age, race, 

ethnicity, gender, sexual orientation, 

disability, and cultural, religious, or 

socioeconomic status. Requests for 

reasonable accommodation to enable 

participation on the Committee should 

be indicated in the nomination 

submission. 

Member Terms: Non-Federal public 

members of the Committee serve for a 

term of 3 years, and may serve for an 

unlimited number of terms if 

reappointed. Members may serve after 

the expiration of their terms, until their 

successors have taken office. 

Meetings and Travel: As specified by 

Public Law 113–166, the MDCC ‘‘shall 

meet no fewer than two times per 

calendar year.’’ Travel expenses are 

provided for non-federal public 

Committee members to facilitate 

attendance at in-person meetings. 

Members are expected to make every 

effort to attend all full committee 

meetings, twice per year, either in 

person or via remote access. 

Participation in relevant subcommittee, 

working and planning group meetings, 

and workshops, is also encouraged. 

Submission Instructions and 

Deadline: Nominations are due by COB 

February 27, 2015, and should be sent 

to Glen Nuckolls, Ph.D., by email to 

nuckollg@ninds.nih.gov. Nominations 

must include contact information for the 

nominee, a current curriculum vitae or 

resume of the nominee and a paragraph 

describing the qualifications of the 

person to represent some portion(s) of 

the muscular dystrophy research and 

patients communities. 

More information about the MDCC is 

available at http://www.ninds.nih.gov/

about_ninds/groups/mdcc/. 

Dated: January 25, 2015. 

Walter J. Koroshetz, 

Acting Director, National Institute of 

Neurological Disorders and Stroke, National 

Institutes of Health. 

[FR Doc. 2015–01960 Filed 1–30–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of HHS-Certified 

Laboratories and Instrumented Initial 

Testing Facilities Which Meet Minimum 

Standards To Engage in Urine Drug 

Testing for Federal Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies federal 

agencies of the laboratories and 

Instrumented Initial Testing Facilities 

(IITF) currently certified to meet the 

standards of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs (Mandatory Guidelines). The 

Mandatory Guidelines were first 

published in the Federal Register on 

April 11, 1988 (53 FR 11970), and 

subsequently revised in the Federal 

Register on June 9, 1994 (59 FR 29908); 

September 30, 1997 (62 FR 51118); 

April 13, 2004 (69 FR 19644); November 

25, 2008 (73 FR 71858); December 10, 

2008 (73 FR 75122); and on April 30, 

2010 (75 FR 22809). 

A notice listing all currently HHScertified laboratories and IITFs is 

published in the Federal Register 

during the first week of each month. If 

any laboratory or IITF certification is 

suspended or revoked, the laboratory or 

IITF will be omitted from subsequent 

lists until such time as it is restored to 

full certification under the Mandatory 

Guidelines. 

If any laboratory or IITF has 

withdrawn from the HHS National 

Laboratory Certification Program (NLCP) 

during the past month, it will be listed 

at the end and will be omitted from the 

monthly listing thereafter. 

This notice is also available on the 

Internet at http://beta.samhsa.gov/

workplace. 

FOR FURTHER INFORMATION CONTACT: 

Giselle Hersh, Division of Workplace 

Programs, SAMHSA/CSAP, Room 7– 

1051, One Choke Cherry Road, 

Rockville, Maryland 20857; 240–276– 

2600 (voice), 240–276–2610 (fax). 

SUPPLEMENTARY INFORMATION: The 

Mandatory Guidelines were initially 

developed in accordance with Executive 

Order 12564 and section 503 of Public 

Law 100–71. The ‘‘Mandatory 

Guidelines for Federal Workplace Drug 

Testing Programs,’’ as amended in the 

revisions listed above, requires strict 

standards that laboratories and IITFs 

must meet in order to conduct drug and 

specimen validity tests on urine 

specimens for federal agencies. 

To become certified, an applicant 

laboratory or IITF must undergo three 

rounds of performance testing plus an 

on-site inspection. To maintain that 

certification, a laboratory or IITF must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories and IITFs in the 

applicant stage of certification are not to 

be considered as meeting the minimum 

requirements described in the HHS 

Mandatory Guidelines. A HHS-certified 

laboratory or IITF must have its letter of 

certification from HHS/SAMHSA 

(formerly: HHS/NIDA), which attests 

that it has met minimum standards. 

In accordance with the Mandatory 

Guidelines dated November 25, 2008 

(73 FR 71858), the following HHScertified laboratories and IITFs meet the 

minimum standards to conduct drug 

and specimen validity tests on urine 

specimens: 

HHS-Certified Instrumented Initial 

Testing Facilities 

Gamma-Dynacare Medical Laboratories, 

6628 50th Street NW., Edmonton, AB 

Canada T6B 2N7, 780–784–1190. 

HHS-Certified Laboratories 

ACM Medical Laboratory, Inc., 160 

Elmgrove Park, Rochester, NY 14624, 

585–429–2264. 

Aegis Analytical Laboratories, Inc., 345 

Hill Ave., Nashville, TN 37210, 615– 

255–2400, (Formerly: Aegis Sciences 

Corporation, Aegis Analytical 

Laboratories, Inc., Aegis Analytical 

Laboratories). 

Alere Toxicology Services, 1111 Newton 

St., Gretna, LA 70053, 504–361–8989/ 

800–433–3823, (Formerly: Kroll 

Laboratory Specialists, Inc., 

Laboratory Specialists, Inc.). 

Alere Toxicology Services, 450 

Southlake Blvd., Richmond, VA 

23236, 804–378–9130, (Formerly: 

Kroll Laboratory Specialists, Inc., 

Scientific Testing Laboratories, Inc.; 

Kroll Scientific Testing Laboratories, 

Inc.). 

Baptist Medical Center-Toxicology 

Laboratory, 11401 I–30, Little Rock, 

AR 72209–7056, 501–202–2783, 

(Formerly: Forensic Toxicology 

Laboratory Baptist Medical Center). 

Clinical Reference Lab, 8433 Quivira 

Road, Lenexa, KS 66215–2802, 800– 

445–6917. 

DrugScan, Inc., 200 Precision Road, 

Suite 200, Horsham, PA 19044, 800– 

235–4890. 

ElSohly Laboratories, Inc., 5 Industrial 

Park Drive, Oxford, MS 38655, 662– 

236–2609. 

mstockstill on DSK4VPTVN1PROD with NOTICES